Prof. Ton Bisseling is a distinguished Professor at the Laboratory of Molecular Biology, Wageningen University & Research. His research focuses on plant-microbe symbiosis, particularly root nodule development in legumes, mycorrhizal interactions, and the genetic mechanisms underlying symbiotic relationships. He has supervised over 70 PhD candidates, including ongoing projects like 'The role of endodermis in mycorrhizal symbiotic interactions' and 'Recruiting microbial communities to combat soil salinization.' Key research interests include understanding symbiotic gene regulation, auxin biosynthesis in nodules, and the role of strigolactones in plant-microbe communication. His work bridges fundamental biology with agricultural applications, addressing sustainable crop production challenges. Bisseling has contributed to 431 research outputs spanning articles, datasets, and book chapters. Notable datasets include RNA sequencing studies on ectomycorrhizal roots and strigolactone biosynthesis. He actively engages in public discourse on topics like nitrogen fixation and Chinese PhD student recruitment in Dutch academia. Current projects involve microbial community analysis in saline agriculture and citrus pathogen mechanisms. His lab collaborates globally, with recent studies in China, the Netherlands, and Saudi Arabia.
Lan Guan is a Professor at Texas Tech University Health Sciences Center in the Department of Cell Physiology and Molecular Biophysics within the School of Medicine. He also serves as Co-Director of the Center for Membrane Protein Research. His research focuses on membrane proteins, which constitute approximately 30% of all eukaryotic proteins and play crucial roles in many aspects of cell function. Dr. Guan's research seeks to understand the mechanisms of solute transport and lay the foundation for advances in disease treatment and human health. He employs an integrated approach including cryo-EM single-particle analysis, X-ray crystallography, ligand binding, molecular dynamics simulations, thermodynamics, genetic engineering, novel amphiphiles, and many other biochemical & biophysical analyses. His current research focuses on cation-coupled bacterial and human transporters. Dr. Guan is currently supported by an NIGMS MIRA R35 Award (2024). His publication record demonstrates expertise in membrane protein structure and function, particularly with melibiose transporters (MelB) and their mechanisms. His work spans structural biology, biochemistry, and biophysics, with significant contributions to understanding membrane transport mechanisms. His research has led to important insights into membrane protein structure-function relationships, particularly in sugar transporters. Dr. Guan's work has implications for understanding fundamental biological processes and potential therapeutic applications related to membrane transport. NIGMS MIRA R35 Award 2024 Dr. Guan actively collaborates with researchers across disciplines and institutions, as evidenced by his extensive publication record with numerous co-authors. His work bridges structural biology, biochemistry, and biophysics to advance our understanding of membrane protein function. He is affiliated with the Center for Membrane Protein Research, where he contributes to advancing methodologies for studying these challenging but critically important biological molecules. His work on novel amphiphiles and detergent design has helped overcome technical barriers in membrane protein research.
Professor David Ackerley (Victoria University of Wellington) is a leading microbiologist and enzyme engineer specializing in directed evolution of bacterial enzymes for biotechnological applications. As Biotechnology Programme Director since 2006, he lectures in foundational courses like BTEC101 and BTEC201. Academic rank: Professor of Biotechnology Institutional affiliation: Victoria University of Wellington Research focus areas: Microbial Biotechnology, Drug Discovery, Synthetic Biology His research employs Darwinian evolutionary principles to engineer enzymes with enhanced activities, particularly targeting non-ribosomal peptide synthetases and nitroreductases for antibiotic development and cancer therapy. Recent work explores metagenomic domain substitution in pyoverdine biosynthesis and Purpuramine R from marine sponges. Key publications demonstrate innovations in metagenomic library construction , CRISPR screening for regeneration genes, and structural characterization of engineered enzymes. His team has developed NTR 2.0 , a high-efficacy nitroreductase for targeted cell ablation. Current research projects include: Clean solutions from dirty genes: Plastic-degrading enzyme discovery Engineering enzymes for CAR T-cell-chemotherapy synergy Repurposing niclosamide against Gram-negative superbugs Grants from the Health Research Council of New Zealand, Royal Society of New Zealand, and Cancer Society of NZ support his work. Collaborations span biomedical research, synthetic biology, and environmental applications.
Pia Vogel is a Professor in the Department of Biological Sciences at Southern Methodist University (SMU), where she leads research on nucleotide-binding proteins using Electron Spin Resonance spectroscopy and molecular modeling. Her work focuses on elucidating structural mechanisms in ATP synthase, multidrug resistance transporters, and calcium channels with biomedical applications in cancer therapy and neurodegenerative diseases. Education: Ph.D., University of Kaiserlautern Dr. Vogel's research program investigates three interconnected domains: the rotary mechanics of FoF1-ATP synthase (particularly the external stalk subunit b-dimer), the structural basis of multidrug resistance in P-glycoprotein and MRPs, and ATP-regulated calcium release via ryanodine receptors. Her laboratory employs site-specific spin labeling, ESR spectroscopy, and computational modeling to resolve protein dynamics and interactions at molecular resolution, contributing to understanding energy transduction in ATP synthase and mechanisms of drug resistance. Analysis of her 15 most recent publications (2020-2025) reveals a dominant focus on developing and characterizing P-glycoprotein and BCRP inhibitors to overcome chemotherapy resistance in cancer. These studies integrate computational screening, ATPase assays, and cell-based models to evaluate inhibitor efficacy, with emerging applications in Alzheimer's research through amyloid-β transport studies. The work demonstrates consistent methodological synergy between biophysical characterization and therapeutic development. Dr. Vogel maintains an active research group supported by sustained funding, evidenced by continuous publication output and laboratory infrastructure. Her team employs multidisciplinary approaches spanning biophysics, biochemistry, and computational biology to address fundamental questions in membrane protein function. Her laboratory facilities in DLSB 221 include specialized Electron Spin Resonance instrumentation and dual Linux computing clusters for molecular dynamics simulations. The research environment supports collaborative projects extending her work into cancer therapeutics and neurodegenerative disease mechanisms through partnerships with clinical and computational researchers.
Ueli Grossniklaus is an Ordinary Professor at the University of Zurich within the Faculty of Mathematical and Natural Sciences , affiliated with the Department of Plant and Microbiology . His work focuses on plant developmental biology, particularly epigenetic and genetic mechanisms governing reproduction and adaptation. Key Courses: Epigenetics, Plant Biology Workshop, Group Seminars on Current Research Laboratory Techniques: Advanced methods in plant cell mechanics, transcriptomics, and genome editing Research Interests span plant epigenetics, reproductive biology, and the interplay between environmental stress and genetic regulation. He investigates: Mechanistic control of gametogenesis and fertilization Epigenetic contributions to plant adaptation Evolutionary implications of asexual reproduction Biophysical forces in plant cell growth Publication Trends (2025–2018) reveal expertise in: Arabidopsis and fern model systems Epigenetic regulation (DNA methylation, histone dynamics) Apomixis and hybrid seed failure mechanisms Biomechanics of pollen tubes and carnivorous plants Genome editing tools (CRISPR) and long-read sequencing Scientific Collaborations include interdisciplinary projects on: Microfluidic devices for plant cell analysis Gene drive ecology and ethics 3D imaging of plant reproductive structures Advising and Grants focus on mentoring through research internships in developmental biology, genetics, and systems biology. His lab engages in: Epigenetic response to environmental stress Cell wall mechanics in reproduction Computational modeling of plant growth Laboratory Teams integrate plant biologists, bioengineers, and computational scientists to study: Mechanistic gene regulation Evolutionary developmental biology Microrobotics for cellular force measurement
Luca Varani is a Professor and Group Leader of the Structural Biology group at the Institute for Research in Biomedicine (IRB), affiliated with the Università della Svizzera italiana in Bellinzona, Switzerland. His research focuses on understanding the molecular mechanisms of antibody-pathogen interactions and engineering novel therapeutic antibodies. Education: Chemistry degree from University of Milan, PhD from MRC-Laboratory of Molecular Biology (University of Cambridge) Former postdoc at Stanford with EMBO fellowship Founder of CLBiotech (2022), a nanobody discovery and engineering startup Varani's research spans structural biology, immunology, and biophysics with emphasis on viral pathogenesis and antibody engineering. His work combines experimental and computational approaches to study antibody-antigen interactions, particularly against emerging pathogens like SARS-CoV-2, Zika, and Dengue viruses. His group has pioneered structure-guided antibody engineering techniques that have led to multiple high-impact publications in journals like Nature, Cell, and Science. Analysis of Varani's recent publications reveals a strong focus on SARS-CoV-2 antibody responses, with significant contributions to understanding neutralizing mechanisms, viral escape, and therapeutic antibody development. His work also extends to prion diseases, cancer immunology, and flaviviruses, demonstrating a multidisciplinary approach that bridges structural biology with translational medicine. As a reviewer for high-impact journals and international granting agencies, Varani contributes significantly to the scientific community. He also serves as an evaluator for European startup accelerator programs and consults for antibody biotechnology companies, translating academic research into practical applications. Varani leads a highly multidisciplinary research team that employs techniques ranging from NMR spectroscopy and X-ray crystallography to cellular assays and computational modeling. His laboratory has been instrumental in developing bispecific antibodies against SARS-CoV-2 and other pathogens, with several candidates advancing toward clinical trials.
Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.
Anne Berit C. Samuelsen serves as Associate Professor at the Department of Pharmacy, University of Oslo, where she also holds the position of Head of Education. Her academic foundation includes a Cand.pharm. degree and Dr.scient. doctorate, establishing her expertise in pharmaceutical sciences. Her research centers on polysaccharides from natural sources—particularly higher plants, cereals, and fungi (Basidiomycota)—with specialized focus on β-glucans. Key interests include carbohydrate chemistry, pharmacognosy, and the development of biopolymer-based pharmaceutical applications. Her work bridges fundamental structural characterization with practical drug delivery solutions, notably through liposome coating technologies and immunomodulatory compound development. Recent publications reveal a strong trajectory in fungal polysaccharide research, particularly with Pleurotus eryngii and Albatrellus ovinus species. Her team employs advanced techniques like diffusion-ordered NMR spectroscopy to analyze polysaccharide structures while investigating biological activities related to immune receptor binding (Dectin-1, Toll-like receptors) and therapeutic applications. This work demonstrates consistent output in high-impact journals including Carbohydrate Polymers and ACS Applied Bio Materials . She actively contributes to academic instruction through courses such as FARM1150 (Pharmaceutically Oriented Biochemistry), FARM3100 (Pharmacognosy), and FARM5200 (Use of Biopolymers in Pharmaceuticals). Her leadership extends to the Bioactive Natural Substances and Health Effects (BioNatH) research group and the Glyconor Consortium, where she investigates natural product applications for health improvement.
Manuel Kleiner is an Associate Professor in the Department of Plant and Microbial Biology at North Carolina State University. His research focuses on metabolic and physiological interactions in host-microbe systems, microbial ecology, and the application of metagenomics and high-resolution mass spectrometry to study complex microbiota-host relationships. Research Highlights: Development of metaproteomic techniques to quantify protein expression, analyze community structure via biomass contributions, and track isotope ratios to understand nutrient flow between hosts and microbiota. Creator of the "transductomics" approach to detect horizontal gene transfer via viral transduction in intestinal systems. Collaborates with researchers such as Theriot, Sartor, Sheikh, Ziegler, and Gonzalez. Recent Trends: His 2025 publications emphasize gut microbiome dynamics, maize root-microbe interactions, transplantation biology, and advancements in metaproteomic methodologies. Key themes include dietary impacts on microbiota, stable isotope probing, and synthetic microbial communities for plant and human health. Laboratory Tools: The Kleiner Lab utilizes quantitative metagenomics, high-resolution mass spectrometry, and computational modeling to dissect functional interactions in symbiotic systems across diverse environments, from marine organisms to agricultural crops.
Ehud Gazit is a distinguished Professor in the Department of Molecular Microbiology and Biotechnology at Tel Aviv University's Faculty of Life Sciences. He holds the Chair for Nano-Biology and serves as Vice President for Research and Development at Tel Aviv University. Professor Gazit has held numerous prestigious visiting appointments including at Umeå University, Fudan University, and Cambridge University. His academic journey began with a B.Sc. (summa cum laude) from Tel Aviv University's Special University Program for Outstanding Students in 1991, followed by a Ph.D. (with distinction) from the Weizmann Institute of Science in 1997, and postdoctoral training at MIT from 1997-2000. Professor Gazit's research focuses on molecular structure and self-assembly at the nano-scale, particularly examining protein folding, unfolding, and misfolding phenomena. His laboratory investigates the mechanisms and significance of protein unfolding and misfolding, with experimental systems including bacterial toxin-antidote systems, type II diabetes-related amyloidogenic proteins, and the VHL tumor suppressor protein. His work bridges fundamental biochemistry with nanotechnology applications, exploring how molecular self-assembly can be harnessed for technological innovation. His recent publications demonstrate a strong trajectory in peptide-based nanomaterials, with particular emphasis on amyloid formation mechanisms, peptide self-assembly for functional materials, and therapeutic applications targeting neurodegenerative diseases. His work spans multiple disciplines including biochemistry, nanotechnology, materials science, and biomedical engineering, showing increasing integration of fundamental research with practical applications. Professor Gazit has received numerous prestigious awards including: 2020 Landau Prize in Sciences and Arts in the Field of Healthy Aging 2019 Rappaport Prize for Excellence in Biomedical Research 2018 Foreign Fellow of the National Academy of Sciences, India 2016 ERC Advanced Grant from the European Research Council 2015 Elected Member of the European Molecular Biology Organization (EMBO) Professor Gazit has been actively involved in mentoring students and researchers, as evidenced by his extensive publication record with numerous collaborators. He has secured significant research funding including an ERC Advanced Grant. His professional activities include editorial board memberships for journals including Journal of Peptide Science, Nanoscience & Nanotechnology - Asia, and Amyloid. He previously served as Chief Scientist of the Ministry of Science and Technology (2012-2014). His laboratory has developed innovative approaches to studying molecular self-assembly, with particular expertise in peptide nanostructures. The research team has made significant contributions to understanding amyloid formation mechanisms while simultaneously developing novel biomaterials with applications ranging from electronics to medicine. They have established strong collaborations with research groups worldwide, creating a dynamic interdisciplinary research environment focused on the intersection of biology and nanotechnology.
Bertrand Coste is a CNRS Researcher at the Cognitive Neuroscience Laboratory (Aix-Marseille University/CNRS), specializing in mechanosensation and ion channel biology. He developed pioneering techniques to study mechanically activated ion channels, notably discovering the PIEZO1 and PIEZO2 channels with Prof. Ardem Patapoutian, which contributed to the 2021 Nobel Prize in Physiology or Medicine. His current work focuses on pain perception mechanisms and cardiovascular functions of PIEZO channels. Education: Completed his PhD at the Laboratoire de neurophysiologie cellulaire in Marseille, followed by postdoctoral research at the Scripps Research Institute, CA (2007–2012). Research Interests: Molecular basis of mechanosensation, mechanosensitive ion channels (PIEZO family), pain signaling, and cardiovascular physiology. His studies bridge molecular neurobiology with clinical applications in chronic pain management and genetic disorders linked to mechanosensory defects. Publications highlight advancements in PIEZO channel structure-function relationships, their roles in sensory perception, and contributions to pathologies like hereditary stomatocytosis and arthrogryposis. His work integrates genetics, cell biology, and biophysics to decode mechanical signaling pathways. Received the Brixham Foundation 2022 Award (Fondation pour la Recherche Médicale) for research on pain mechanisms. Collaborates with interdisciplinary teams at the CNRS and Aix-Marseille University, advancing translational neuroscience initiatives.
David N. Langelaan is an Associate Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University, within the Faculty of Medicine. He holds a PhD from Dalhousie University and has been a department member since 2016. His research focuses on structural biology, protein-protein interactions, cellular signaling, and protein engineering. Key projects include hydrophobin characterization and engineering, studying MITF's role in melanoma and development, and analyzing rhodoquinone biosynthesis in anaerobic environments. Education: PhD, Dalhousie University. Research Themes: Structural biology, protein assemblies, microbial biochemistry, cancer biology. His lab employs techniques like NMR spectroscopy, X-ray crystallography, and isothermal titration calorimetry. Current lab members include graduate students (Raymond He, Trilok Neupane) and honours students (Alex Bouchard, Janani Venkat). Funding is provided by agencies such as NSERC, CFI, and the Dalhousie Medical Research Foundation. Publications highlight contributions to antimicrobial mechanisms, transcription factor signaling, and hydrophobin self-assembly. Recent work examines MITF coactivator interactions and rhodoquinone biosynthesis pathways in bacteria.
Hartmut Michel is a Scientific Member and Director at the Max Planck Institute of Biophysics in Frankfurt, Germany, where he leads the Department of Molecular Membrane Biology. He has held this position since 1987 and has also served as an Adjunct Professor at the University of Frankfurt since 1989. Michel received his PhD in Biochemistry from the University of Wuerzburg in 1977 and completed postdoctoral work there before joining the Max Planck Institute of Biochemistry as a research associate. Michel's research focuses on membrane proteins, particularly in the areas of structural biology, biochemistry, photosynthesis, and respiratory complexes. His work has centered on understanding the structure and function of membrane proteins, especially cytochrome c oxidase and photosynthetic reaction centers. He pioneered techniques for membrane protein crystallization and has made significant contributions to understanding electron transfer processes and proton pumping mechanisms in respiratory enzymes. His publication record spans over four decades, with recent work focusing on cryo-EM structural analysis of membrane proteins including cytochrome bd oxidases, ABC transporters, and photosynthetic complexes. The research demonstrates a consistent trajectory from fundamental structural studies toward understanding functional mechanisms and applications in areas like antibiotic development and bioenergetics. Scientific Awards 1986 Leibniz Prize of the German Research Foundation 1988 Otto Bayer Prize (with Johann Deisenhofer) 1988 Nobel Prize in Chemistry (with Johann Deisenhofer and Robert Huber) 2008 Keilin Medal of the British Biochemical Society Honorary doctorates from the Universities of Wuerzburg and Bologna Michel has maintained an active research program with numerous collaborations across Europe and internationally. His laboratory has developed innovative approaches for membrane protein expression, purification, and structural characterization. The team has made significant contributions to understanding the structure-function relationships in respiratory chain components and photosynthetic apparatus. His department at the Max Planck Institute serves as a leading center for membrane protein research, with specialized facilities for protein crystallization, cryo-electron microscopy, and functional characterization of membrane proteins. The research has implications for understanding fundamental biological energy conversion processes and developing new therapeutic approaches targeting membrane proteins.
Dr. Reuben Leveson-Gower is an Assistant Professor in the Biocatalysis Section of the Department of Biotechnology at TU Delft. His research focuses on designing enzymes for novel chemical reactions, combining synthetic chemistry principles with biological systems to advance green chemistry and deepen understanding of enzyme mechanisms. He holds a PhD from the University of Groningen (cum laude) and has expertise in protein engineering, directed evolution, and computational enzymology. Notable awards include the FEBS Short-Term Fellowship and the Salters’ Institute Graduate Prize. Education: PhD in Chemistry (Groningen), MChem with First Class Honors (Durham). Research Focus: Artificial enzyme design, biocatalytic reactions, protein engineering, and sustainable chemical processes. Awards: FEBS Fellowship, Salters’ Prize, cum laude PhD distinction. His lab employs interdisciplinary techniques such as synthetic chemistry, bioinformatics, and mechanistic enzymology to evolve enzymes for non-natural reactions. Key projects include developing Friedel-Crafts alkylases and boron-catalyzed systems. Collaborations emphasize translational applications in industry and environmental sustainability.
Brenda Schulman is a Professor and Director of the Molecular Machines and Signaling Pathways department at the Max Planck Institute of Biochemistry in Martinsried, Germany. She also holds an honorary professorship at the Technical University of Munich's Department of Chemistry and serves as Adjunct Faculty at St. Jude Children's Research Hospital in Memphis, TN, USA. Her research focuses on understanding how ubiquitin and ubiquitin-like proteins regulate cellular processes through protein modification. Dr. Schulman's research interests center on structural biology of the ubiquitin-proteasome system and ubiquitin-like proteins. Her work has shown that hundreds of dynamic multiprotein complexes are transiently converted into different conformations by specialized regulatory factors that control ubiquitin and ubiquitin-like proteins, thereby monitoring virtually all processes in cell biology. She combines biochemical reconstitution, structural analysis, enzymology, protein design, cell biology, and genetics to understand how these molecular machines function. Her research has significant implications for understanding diseases such as cancer, neurodegenerative disorders, and viral infections where defects in ubiquitin pathways are implicated. Her extensive publication record demonstrates expertise in ubiquitin signaling, protein degradation mechanisms, structural biology of E3 ligases, and molecular machines. Her work spans from fundamental mechanisms of ubiquitin chain formation to therapeutic applications in targeted protein degradation. Among her numerous scientific accolades are the Feldberg Prize for Anglo-German Scientific Exchange (2025), ERC Advanced Grant (2023), Louis-Jeantet Prize for Medicine (2023), Gottfried Wilhelm Leibniz Prize (2019), and election to the National Academy of Sciences (2014). She has also received the Dorothy Crowfoot Hodgkin Award from The Protein Society and has been an Investigator of the Howard Hughes Medical Institute. Dr. Schulman leads an active research group that has produced numerous high-impact publications in top journals including Nature, Cell, and Nature Structural & Molecular Biology. Her team has made significant contributions to understanding the structural mechanisms of ubiquitin transfer, E3 ligase specificity, and the role of ubiquitin in cellular quality control pathways. Current research in her lab focuses on deciphering the ubiquitin code and developing novel approaches for targeted protein degradation.
